Published in Vaccine Weekly, April 24th, 2002
Sanofi-Synthelabo's exercising of their option triggers the payment of milestones, the reimbursement of clinical development costs previously incurred by IDM for this cell drug as well as the reimbursement of the clinical development program as it moves forward.
Following the announcement of their partnership, Sanofi-Synth_labo and IDM agreed that this advanced program is particularly interesting to Sanofi-Synth_labo for the following...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly